Briefing
Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.
6-month DFS by 4-to-12-week ctDNA dynamics: 98% if negative-to-negative (n=618), 100% if positive-to-negative (n=58), 59% if negative-to-positive (n=32), and 45% if positive-to-positive (n=78); HR 52.3 comparing conversion to clearance vs persistent positivity (P<0.001). Among 4-week MRD-positive patients, 12-week clearance was 57% (54/95) with adjuvant chemotherapy vs 8% (7/93) without (P<0.001). 6-month DFS in 4-week MRD-positive patients was 84% vs 34% with vs without ACT (HR 0.15, P<0.001).
- n: 1,365 patients enrolled June 2020-April 2021 (this analysis); median follow-up 6.6 months
- Assay: Signatera (tumor-informed)